T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor - PubMed (original) (raw)
T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor
B J Poiesz et al. Proc Natl Acad Sci U S A. 1980 Nov.
Abstract
Long-term growth of lymphoblastoid T cells from tissue samples from six of six patients with cutaneous T-cell lymphoma (CTCL) and six of six patients with acute T-lymphoblastic leukemia (ALL) has been achieved by using partially purified mitogen-free human T-cell growth factor (pp-TCGF). One cell line, CTCL-2, is now independent of added growth factor; the others continue to show absolute dependency on its presence. All lines have been in continuous culture for at least 4 months and some for > 1 year. They are erythrocyte-rosette positive and are negative for Epstein-Barr virus nuclear antigen. Most of the lines are negative for Fc and complement receptors and for surface immunoglobulin except that CTCL-1 and CTCL-2 have some cells positive for these cell surface markers. Results of histochemical studies on these cell lines are similar to the known patterns for fresh cells from their disease of origin. Cell line CTCL-3 has an abnormal karyotype, but no detectable chromosomal abnormalities were found in the other lines, consistent with the karyologic features of their clinical sources. Because T cells from normal donors do not respond to pp-TCGF unless the cells are first "activated" by a lectin mitogen such as phytohemagglutinin or an antigen, the direct response to pp-TCGF of T cells from patients with T-cell neoplasias suggests that the cell lines represent a transformed neoplastic cell population. Although some of the cell lines may be normal T cells activated by the malignant cells, the morphologic and histochemical properties of the cell lines, the abnormal karyotype of CTCL-3, and the independent growth of CTCL-2 support the conclusion that most of these cell lines are of malignant origin.
Similar articles
- Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.
Haynes BF, Bunn P, Mann D, Thomas C, Eisenbarth GS, Minna J, Fauci AS. Haynes BF, et al. J Clin Invest. 1981 Feb;67(2):523-30. doi: 10.1172/JCI110062. J Clin Invest. 1981. PMID: 6970206 Free PMC article. - Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor.
Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, Gallo RC. Gootenberg JE, et al. J Exp Med. 1981 Nov 1;154(5):1403-18. doi: 10.1084/jem.154.5.1403. J Exp Med. 1981. PMID: 6975346 Free PMC article. - Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Jawed SI, et al. J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review. - Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL. Edelson RL. Ann N Y Acad Sci. 2001 Sep;941:1-11. Ann N Y Acad Sci. 2001. PMID: 11594563 Review.
Cited by
- Opportunities for improving techniques for interspecies extrapolation in the risk assessment process.
Gibson JE, Starr TB. Gibson JE, et al. Environ Health Perspect. 1988 Apr;77:99-105. doi: 10.1289/ehp.887799. Environ Health Perspect. 1988. PMID: 3289913 Free PMC article. Review. - Human T-cell leukemia virus type 1 Tax enhances serum response factor DNA binding and alters site selection.
Winter HY, Marriott SJ. Winter HY, et al. J Virol. 2007 Jun;81(11):6089-98. doi: 10.1128/JVI.02179-06. Epub 2007 Mar 21. J Virol. 2007. PMID: 17376895 Free PMC article. - Convicting a human tumor virus: guilt by association?
Blaho JA, Aaronson SA. Blaho JA, et al. Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7619-21. doi: 10.1073/pnas.96.14.7619. Proc Natl Acad Sci U S A. 1999. PMID: 10393867 Free PMC article. Review. No abstract available. - Incidence of adult T-cell leukemia/lymphoma in nonendemic areas.
Yoshida N, Chihara D. Yoshida N, et al. Curr Treat Options Oncol. 2015 Feb;16(2):7. doi: 10.1007/s11864-014-0321-5. Curr Treat Options Oncol. 2015. PMID: 25762122 Review. - Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1.
Zagury JF, Franchini G, Reitz M, Collalti E, Starcich B, Hall L, Fargnoli K, Jagodzinski L, Guo HG, Laure F, et al. Zagury JF, et al. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5941-5. doi: 10.1073/pnas.85.16.5941. Proc Natl Acad Sci U S A. 1988. PMID: 3261862 Free PMC article.
References
- J Natl Cancer Inst. 1969 Dec;43(6):1297-305 - PubMed
- Immunology. 1970 Oct;19(4):637-50 - PubMed
- Am J Clin Pathol. 1971 Mar;55(3):283-90 - PubMed
- Nat New Biol. 1972 Nov 15;240(98):67-72 - PubMed
- Int J Cancer. 1973 May;11(3):499-520 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous